Private Equity’s New Play in Medtech

Published in MedTech Strategist

Author: Wendy Diller

Abstract:
Private equity buyers have jumped into the medical device sector in 2025, flush with capital and plans for revamping companies in an unforgiving, volatile macroenvironment. Blackstone and TPG’s take out of publicly traded Hologic is a high-profile example of the opportunity.

News June 23, 2026

Outcome Capital Named Top Life Sciences Advisory and Strategic Investment Banking Solutions Provider for 2026

Outcome Capital has been named Life Sciences Review’s exclusive recipient of the “Top Life Sciences Advisory and Strategic Investment Banking Solutions 2026” award, recognizing its unique approach to helping life sciences companies move innovations from development to commercialization. The firm combines scientific, clinical, operational, and financial expertise to support emerging and growth-stage companies with fundraising, […]

Outcome Capital Life Science Pulse

Outcome Capital Life Science Market Pulse July 2026 Click to view our LifeSciences Pulse Newsletter

Download

Private Equity’s New Play in Medtech

Private equity buyers have jumped into the medical device sector in 2025, flush with capital and plans for revamping companies in an unforgiving, volatile macroenvironment. Blackstone and TPG’s take out of publicly traded Hologic is a high-profile example of the opportunity.